{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:13:14Z","timestamp":1793812394028,"version":"4.6.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Follicular dendritic cell sarcoma (FDCS) is a rare malignant neoplasm that was classified by the World Health Organization (WHO) under histiocytic and dendritic cell neoplasms in the 2016 revision. Considering the rarity of this tumor, there is no standardized treatment. It is usually treated by complete surgical resection. Adjuvant chemotherapy and radiotherapy are alternative methods. Immune checkpoint inhibitors (ICIs) represented by the programmed death receptor 1\/programmed death ligand 1 (PD-1\/PD-L1) antibody have achieved significant clinical benefits in a variety of solid tumors. However, reports on the treatment of FDCS with ICIs are rare. FDCS often expresses high levels of PD-L1, which provides a rationale to use immunotherapy in cases of FDCS. Here, we present a 51-year-old Filipino-Chinese man with FDCS who was treated with multimodal treatment, including the PD-1 inhibitor pembrolizumab and achieved a relatively long disease-free survival of 24 months. This case emphasizes that the application of ICIs under the guidance of NGS technology seems to be a meaningful treatment option for patients with FDCS.<\/jats:p>","DOI":"10.3389\/fonc.2022.816903","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T10:58:11Z","timestamp":1646132291000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Response of Tonsil Follicular Dendritic Cell Sarcoma to Multimodal Treatment Including Pembrolizumab: A Case Report and Literature Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Nanxiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare Cancers are Not So Rare: The Rare Cancer Burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951X-331","article-title":"Follicular Dendritic Cell Sarcoma","volume":"113","author":"Facchetti","year":"2021","journal-title":"Pathologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00000433-198603000-00024","article-title":"A Primary Lymph Node Malignancy With Features Suggestive of Dendritic Reticulum Cell Differentiation. A report of 4\u00a0cases","volume":"122","author":"Monda","year":"1986","journal-title":"Rep Am J Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880489","article-title":"Extranodal Follicular Dendritic Cell Sarcoma of the Head and Neck Region: Three New Cases, With a Review of the Literature","volume":"15","author":"Biddle","year":"2002","journal-title":"Modern Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2681","article-title":"Extranodal Follicular Dendritic Cell Sarcoma: A Clinicopathological Report of Four Cases and a Literature Review","volume":"9","author":"Wang","year":"2015","journal-title":"Oncol Lett"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1043\/1543-2165(2008)132[1683:EFDCS]2.0.CO;2","article-title":"Extranodal Follicular Dendritic Cell Sarcoma","volume":"132","author":"Youens","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41416-018-0294-4","article-title":"PD-Loma: A Cancer Entity With a Shared Sensitivity to the PD-1\/PD-L1 Pathway Blockade","volume":"120","author":"Hirsch","year":"2019","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201710407","article-title":"Immune Checkpoint PD-1\/PD-L1: Is There Life Beyond Antibodies","volume":"57","author":"Konstantinidou","year":"2018","journal-title":"Angew Chem Int Ed Engl"},{"key":"B9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13045-017-0541-9","article-title":"Recent Development in Clinical Applications of PD-1 and PD-L1 Antibodies for Cancer Immunotherapy","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B10","first-page":"476","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th Edition)","volume":"421","author":"Swerdlow","year":"2017","journal-title":"IARC: Lyon"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2559.2002.01418.x","article-title":"Tumours of Histiocytes and Accessory Dendritic Cells: An Immunohistochemical Approach to Classification From the International Lymphoma Study Group Based on 61 Cases","volume":"41","author":"Pileri","year":"2002","journal-title":"Histopathology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199608000-00003","article-title":"Follicular Dendritic Cell Tumor: Report of 13 Additional Cases of a Distinctive Entity","volume":"20","author":"Perez-Ordonez","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2016.05.003","article-title":"Follicular Dendritic Cell Sarcoma: Clinicopathologic Study of 15 Cases With Emphasis on Novel Expression of MDM2, Somatostatin Receptor 2A, and PD-L1","volume":"23","author":"Agaimy","year":"2016","journal-title":"Ann Diagn Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/modpathol.2015.130","article-title":"Targeted Genomic Sequencing of Follicular Dendritic Cell Sarcoma Reveals Recurrent Alterations in NF-\u03bab Regulatory Genes","volume":"29","author":"Griffin","year":"2016","journal-title":"Modern Pathol: An Off J U States Can Acad Pathol Inc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/his.12416","article-title":"Frequent Detection of BRAF(V600E) Mutations in Histiocytic and Dendritic Cell Neoplasms","volume":"65","author":"Go","year":"2014","journal-title":"Histopathology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.05.006","article-title":"Dendritic Cell Sarcoma: A Pooled Analysis Including 462 Cases With Presentation of Our Case Series","volume":"88","author":"Saygin","year":"2013","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.1906","article-title":"Primary Follicular Dendritic Cell Sarcoma of Liver Treated With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Regimen and Surgery","volume":"29","author":"Shinagare","year":"2011","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14672","article-title":"Characteristics, Management, and Outcomes of Patients With Follicular Dendritic Cell Sarcoma","volume":"178","author":"Jain","year":"2017","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-4-6","article-title":"Response of Follicular Dendritic Cell Sarcoma to Gemcitabine and Docetaxel: Report of Two Cases and Literature Review","volume":"4","author":"Conry","year":"2014","journal-title":"Clin Sarcoma Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24115","article-title":"Follicular Dendritic Cell Sarcoma of the Head and Neck: Case Report, Literature Review, and Pooled Analysis of 97 Cases","author":"Pang","year":"2016","journal-title":"Head Neck"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2010.51.4.602","article-title":"Follicular Dendritic Cell Sarcoma of the Tonsil","volume":"51","author":"Eun","year":"2010","journal-title":"Yonsei Med J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000590","article-title":"Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders","volume":"40","author":"Xu","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-234363","article-title":"Follicular Dendritic Cell Sarcoma and its Response to Immune Checkpoint Inhibitors Nivolumab and Ipilimumab","volume":"13","author":"Lee","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4378","article-title":"Disseminated Histiocytoses Biomarkers Beyond BRAFV600E: Frequent Expression of PD-L1","volume":"6","author":"Gatalica","year":"2015","journal-title":"Oncotarget"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653319","article-title":"Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review","volume":"12","author":"Lei","year":"2021","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-16-0301","article-title":"Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas","volume":"15","author":"Laginestra","year":"2017","journal-title":"Mol Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"bcr2016218889","DOI":"10.1136\/bcr-2016-218889","article-title":"Follicular Dendritic Sarcoma Masquerading as Fibrosing Mediastinitis","volume":"2017","author":"Cingam","year":"2017","journal-title":"BMJ Case Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.816903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T10:58:15Z","timestamp":1646132295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.816903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":27,"alternative-id":["10.3389\/fonc.2022.816903"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.816903","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]},"article-number":"816903"}}